Biotron Limited (ASX:BIT) insider Robert Thomas purchased 1,004,793 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The shares were purchased at an average cost of A$0.06 ($0.04) per share, for a total transaction of A$60,287.58 ($42,757.15).
BIT opened at A$0.11 ($0.07) on Friday.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.wkrb13.com/2018/11/10/robert-thomas-purchases-1004793-shares-of-biotron-limited-bit-stock.html.
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus.
Featured Story: Find a Trading Strategy That Works
Receive News & Ratings for Biotron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotron and related companies with MarketBeat.com's FREE daily email newsletter.